5.53
price up icon3.17%   0.17
after-market Dopo l'orario di chiusura: 5.58 0.05 +0.90%
loading
Precedente Chiudi:
$5.36
Aprire:
$5.4088
Volume 24 ore:
295.04K
Relative Volume:
0.26
Capitalizzazione di mercato:
$331.22M
Reddito:
-
Utile/perdita netta:
$-44.80M
Rapporto P/E:
-7.3733
EPS:
-0.75
Flusso di cassa netto:
$-30.67M
1 W Prestazione:
+7.17%
1M Prestazione:
+79.25%
6M Prestazione:
+9.94%
1 anno Prestazione:
+37.91%
Intervallo 1D:
Value
$5.385
$5.55
Intervallo di 1 settimana:
Value
$4.88
$5.6552
Portata 52W:
Value
$1.14
$7.20

Aldeyra Therapeutics Inc Stock (ALDX) Company Profile

Name
Nome
Aldeyra Therapeutics Inc
Name
Telefono
781-761-4904
Name
Indirizzo
131 HARTWELL AVENUE, LEXINGTON, MA
Name
Dipendente
8
Name
Cinguettio
@aldeyraaldx
Name
Prossima data di guadagno
2024-11-18
Name
Ultimi documenti SEC
Name
ALDX's Discussions on Twitter

Confronta ALDX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ALDX
Aldeyra Therapeutics Inc
5.53 321.04M 0 -44.80M -30.67M -0.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-04-03 Aggiornamento Oppenheimer Perform → Outperform
2024-04-02 Ripresa H.C. Wainwright Buy
2022-04-27 Ripresa H.C. Wainwright Buy
2021-02-08 Iniziato H.C. Wainwright Buy
2020-12-16 Iniziato Berenberg Buy
2020-10-30 Iniziato Jefferies Buy
2020-10-16 Iniziato BTIG Research Buy
2020-09-22 Iniziato Alliance Global Partners Buy
2020-05-12 Iniziato Oppenheimer Outperform
2018-12-04 Iniziato Citigroup Buy
2018-09-26 Reiterato Cantor Fitzgerald Overweight
2018-09-13 Iniziato Janney Buy
2018-01-26 Iniziato Seaport Global Securities Buy
2016-09-26 Iniziato H.C. Wainwright Buy
2016-07-01 Iniziato Stifel Buy
2015-07-01 Iniziato Canaccord Genuity Buy
2015-03-25 Iniziato Chardan Capital Markets Buy
2015-03-20 Reiterato H.C. Wainwright Buy
2014-11-18 Iniziato H.C. Wainwright Buy
2014-06-19 Iniziato Aegis Capital Buy
Mostra tutto

Aldeyra Therapeutics Inc Borsa (ALDX) Ultime notizie

pulisher
Jul 23, 2025

What analysts say about Aldeyra Therapeutics Inc. stockUnprecedented growth rates - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Published on: 2025-07-23 18:29:07 - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

Aldeyra Therapeutics Inc. Stock Analysis and ForecastSuperior returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Aldeyra Therapeutics Inc. stock priceHigh-impact stock picks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Is Aldeyra Therapeutics Inc. a good long term investmentHigh-octane financial growth - Autocar Professional

Jul 21, 2025
pulisher
Jul 19, 2025

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - MSN

Jul 19, 2025
pulisher
Jul 18, 2025

FDA accepts Aldeyra's resubmitted reproxalap NDA - Eyes On Eyecare

Jul 18, 2025
pulisher
Jul 17, 2025

FDA accepts for review Aldeyra Therapeutics’ resubmitted new drug application for reproxalap - Optometry Times

Jul 17, 2025
pulisher
Jul 17, 2025

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail

Jul 17, 2025
pulisher
Jul 17, 2025

Aldeyra Therapeutics Announces FDA Acceptance for Review of Repr - GuruFocus

Jul 17, 2025
pulisher
Jul 17, 2025

Aldeyra says dry eye therapy undergoes FDA review (ALDX:NASDAQ) - Seeking Alpha

Jul 17, 2025
pulisher
Jul 17, 2025

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease - Lelezard

Jul 17, 2025
pulisher
Jul 17, 2025

FDA Accepts Aldeyra’s Reproxalap Application for Review - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

FDA Reviews Aldeyra's (ALDX) Reproxalap for Dry Eye Disease | AL - GuruFocus

Jul 17, 2025
pulisher
Jul 17, 2025

FDA accepts Aldeyra’s resubmitted NDA for dry eye disease drug By Investing.com - Investing.com Nigeria

Jul 17, 2025
pulisher
Jul 17, 2025

FDA accepts Aldeyra’s resubmitted NDA for dry eye disease drug - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

FDA Reviews Breakthrough Dry Eye Drug: Aldeyra's Reproxalap Could Transform Treatment Landscape - Stock Titan

Jul 17, 2025
pulisher
Jul 16, 2025

How Aldeyra Therapeutics Inc. stock performs during market volatilityFree Stock Selection - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN

Jul 16, 2025
pulisher
Jul 16, 2025

why aldeyra therapeutics inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail

Jul 16, 2025
pulisher
Jul 15, 2025

Why Aldeyra Therapeutics Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Aldeyra Therapeutics Inc. stock price move sharplyCapital Safe Smart Trades - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Are Medical Stocks Lagging Amgen (AMGN) This Year? - Yahoo Finance

Jul 15, 2025
pulisher
Jul 12, 2025

(ALDX) Trading Report - news.stocktradersdaily.com

Jul 12, 2025
pulisher
Jul 08, 2025

Aldeyra Therapeutics Leads The Pack Among 3 Promising Penny Stocks - simplywall.st

Jul 08, 2025
pulisher
Jul 06, 2025

Market Sentiment Around Loss-Making Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - simplywall.st

Jul 06, 2025
pulisher
Jul 02, 2025

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data - Seeking Alpha

Jul 02, 2025
pulisher
Jun 27, 2025

Aldeyra Shares Climb on FDA Backing for PVRL Drug Trial Design - MSN

Jun 27, 2025
pulisher
Jun 27, 2025

Aldeyra Therapeutics (ALDX) Gets a Buy from JonesTrading - The Globe and Mail

Jun 27, 2025
pulisher
Jun 26, 2025

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma | ALDX Stock News - GuruFocus

Jun 26, 2025
pulisher
Jun 26, 2025

Aldeyra receives FDA special protocol assessment for lymphoma drug - Investing.com

Jun 26, 2025
pulisher
Jun 26, 2025

Aldeyra receives FDA special protocol assessment for lymphoma drug By Investing.com - Investing.com Canada

Jun 26, 2025
pulisher
Jun 25, 2025

Aldeyra (ALDX) Gains FDA Nod for New Cancer Trial | ALDX Stock N - GuruFocus

Jun 25, 2025
pulisher
Jun 21, 2025

When the Price of (ALDX) Talks, People Listen - news.stocktradersdaily.com

Jun 21, 2025
pulisher
Jun 17, 2025

Aldeyra Therapeutics Resubmits Reproxalap NDA in Dry Eye Disease - HCPLive

Jun 17, 2025
pulisher
Jun 17, 2025

Aldeyra resubmits NDA for dry eye disease drug after trial success - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Aldeyra resubmits NDA for dry eye disease drug after trial success By Investing.com - Investing.com South Africa

Jun 17, 2025
pulisher
Jun 17, 2025

Aldeyra Therapeutics (ALDX) Resubmits FDA Application for Dry Ey - GuruFocus

Jun 17, 2025

Aldeyra Therapeutics Inc Azioni (ALDX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Capitalizzazione:     |  Volume (24 ore):